Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Key Takeaway: A class action lawsuit has been filed against aTyr Pharma, Inc. following disappointing results from the EFZO-FIT study, which did not meet its primary endpoint. The decline in stock price, from $6.03 to $1.02, resulted in an 83.2% drop after the announcement revealed misleading statements about the drug Efzofitimod's efficacy. Shareholders who purchased stock during the defined class period are being notified to participate in the lawsuit. The deadline for registering as a lead plaintiff is set for December 8, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • aTyr Pharma's stock price fell dramatically by 83.2% after the announcement regarding Efzofitimod's study results.
  • The allegations suggest that the company misled investors about the efficacy of its drug.
  • The announcement of not meeting primary study endpoints could raise concerns about future regulatory interactions with the FDA.
  • Shareholders are facing potential losses and are encouraged to join a class action lawsuit.

Full Press Release Details

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 7, 2024 to September 12, 2025
ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. The truth emerged on September 15, 2025 (pre-market) when aTyr hosted an investor call announcing that the EFZO-FIT study did not meet its primary endpoint. In pertinent part, defendants announced that the study did not meet the primary endpoint in change from baseline in mean daily OSC dose at week 48. Additionally, aTyr announced that the Company’s next step was to engage with the FDA to determine a path forward, given the disappointing topline results. Following this news, the price of aTyr’s common stock declined from a closing market price of $6.03 per share on September 12, 2025 to $1.02 per share on September 15, 2025, a decline of 83.2% in the span of just a single day.
DEADLINE: December 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/atyr-pharma-inc-loss-submission-form/?id=176102&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ATYR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 8, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for aTyr Pharma shareholders?

The class period for aTyr Pharma shareholders is from November 7, 2024, to September 12, 2025.

What allegations are made against aTyr Pharma?

Allegations include providing false statements about Efzofitimod's efficacy while concealing adverse facts.

When did the truth about aTyr Pharma's drug emerge?

The truth emerged on September 15, 2025, during an investor call regarding EFZO-FIT study results.

When is the deadline to register for the class action?

The deadline to register for the class action is December 8, 2025.

How can shareholders participate in the case?

Shareholders can register online to participate, with no cost or obligation.

Last updated: Nov 10, 2025